Charles River Laboratories ROE 2012-2026 | CRL
Current and historical return on equity (ROE) values for Charles River Laboratories (CRL) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Charles River Laboratories ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2026-06-30 | $-0.24B | $3.09B | -7.73% |
| 2026-03-31 | $-0.19B | $3.22B | -5.77% |
| 2025-12-31 | $-0.15B | $3.29B | -4.44% |
| 2025-09-30 | $-0.09B | $3.36B | -2.68% |
| 2025-06-30 | $-0.08B | $3.45B | -2.17% |
| 2025-03-31 | $-0.04B | $3.55B | -1.04% |
| 2024-12-31 | $0.01B | $3.66B | 0.30% |
| 2024-09-30 | $0.42B | $3.69B | 11.35% |
| 2024-06-30 | $0.44B | $3.57B | 12.24% |
| 2024-03-31 | $0.44B | $3.45B | 12.85% |
| 2023-12-31 | $0.47B | $3.32B | 14.27% |
| 2023-09-30 | $0.47B | $3.17B | 14.97% |
| 2023-06-30 | $0.48B | $3.00B | 16.12% |
| 2023-03-31 | $0.50B | $2.85B | 17.40% |
| 2022-12-31 | $0.49B | $2.72B | 17.83% |
| 2022-09-30 | $0.44B | $2.61B | 16.70% |
| 2022-06-30 | $0.44B | $2.56B | 17.31% |
| 2022-03-31 | $0.42B | $2.48B | 17.04% |
| 2021-12-31 | $0.39B | $2.37B | 16.49% |
| 2021-09-30 | $0.40B | $2.27B | 17.48% |
| 2021-06-30 | $0.40B | $2.13B | 18.57% |
| 2021-03-31 | $0.38B | $1.99B | 18.83% |
| 2020-12-31 | $0.36B | $1.86B | 19.59% |
| 2020-09-30 | $0.30B | $1.74B | 17.32% |
| 2020-06-30 | $0.27B | $1.65B | 16.46% |
| 2020-03-31 | $0.25B | $1.57B | 15.78% |
| 2019-12-31 | $0.25B | $1.51B | 16.71% |
| 2019-09-30 | $0.23B | $1.43B | 16.24% |
| 2019-06-30 | $0.22B | $1.36B | 16.11% |
| 2019-03-31 | $0.23B | $1.29B | 17.74% |
| 2018-12-31 | $0.23B | $1.23B | 18.51% |
| 2018-09-30 | $0.14B | $1.16B | 11.83% |
| 2018-06-30 | $0.13B | $1.10B | 11.73% |
| 2018-03-31 | $0.13B | $1.05B | 12.34% |
| 2017-12-31 | $0.12B | $0.98B | 12.56% |
| 2017-09-30 | $0.20B | $0.93B | 21.35% |
| 2017-06-30 | $0.18B | $0.89B | 20.69% |
| 2017-03-31 | $0.17B | $0.86B | 19.26% |
| 2016-12-31 | $0.16B | $0.83B | 18.61% |
| 2016-09-30 | $0.14B | $0.81B | 17.58% |
| 2016-06-30 | $0.14B | $0.77B | 18.39% |
| 2016-03-31 | $0.16B | $0.73B | 21.11% |
| 2015-12-31 | $0.15B | $0.71B | 21.27% |
| 2015-09-30 | $0.15B | $0.69B | 21.02% |
| 2015-06-30 | $0.14B | $0.68B | 20.56% |
| 2015-03-31 | $0.13B | $0.67B | 18.72% |
| 2014-12-31 | $0.13B | $0.68B | 18.50% |
| 2014-09-30 | $0.12B | $0.67B | 17.53% |
| 2014-06-30 | $0.12B | $0.67B | 17.48% |
| 2014-03-31 | $0.11B | $0.66B | 16.43% |
| 2013-12-31 | $0.10B | $0.65B | 15.94% |
| 2013-09-30 | $0.10B | $0.64B | 16.04% |
| 2013-06-30 | $0.09B | $0.62B | 14.97% |
| 2013-03-31 | $0.10B | $0.60B | 16.01% |
| 2012-12-31 | $0.10B | $0.58B | 16.53% |
| 2012-09-30 | $0.11B | $0.56B | 18.69% |
| 2012-06-30 | $0.10B | $0.55B | 18.65% |
| 2012-03-31 | $0.10B | $0.55B | 18.79% |
| 2011-12-31 | $0.11B | $0.56B | 19.61% |
| 2011-09-30 | $-0.26B | $0.60B | -43.94% |
| 2011-06-30 | $-0.31B | $0.72B | -42.47% |
| 2011-03-31 | $-0.32B | $0.92B | -35.17% |
| 2010-12-31 | $-0.34B | $1.13B | -30.01% |
| 2010-09-30 | $0.02B | $1.30B | 1.85% |
| 2010-06-30 | $0.09B | $1.38B | 6.25% |
| 2010-03-31 | $0.11B | $1.35B | 7.87% |
| 2009-12-31 | $0.11B | $1.31B | 8.73% |
| 2009-09-30 | $-0.57B | $1.27B | -44.54% |
| 2009-06-30 | $-0.56B | $1.42B | -39.30% |
| 2009-03-31 | $-0.54B | $1.59B | -34.25% |
| 2008-12-31 | $-0.53B | $1.76B | -29.81% |
| 2008-09-30 | $0.17B | $1.92B | 8.93% |
| 2008-06-30 | $0.17B | $1.88B | 8.99% |
| 2008-03-31 | $0.16B | $1.83B | 8.66% |
| 2007-12-31 | $0.15B | $1.76B | 8.59% |
| 2007-09-30 | $0.15B | $1.69B | 9.04% |
| 2007-06-30 | $0.09B | $1.63B | 5.70% |
| 2007-03-31 | $0.08B | $1.61B | 5.04% |
| 2006-12-31 | $-0.06B | $1.63B | -3.43% |
| 2006-09-30 | $-0.04B | $1.69B | -2.43% |
| 2006-06-30 | $0.01B | $1.75B | 0.46% |
| 2006-03-31 | $0.01B | $1.77B | 0.79% |
| 2005-12-31 | $0.14B | $1.72B | 8.28% |
| 2005-09-30 | $0.11B | $1.63B | 6.88% |
| 2005-06-30 | $0.11B | $1.32B | 8.04% |
| 2005-03-31 | $0.10B | $1.02B | 9.85% |
| 2004-12-31 | $0.09B | $0.76B | 11.85% |
| 2004-09-30 | $0.09B | $0.51B | 17.94% |
| 2004-06-30 | $0.09B | $0.48B | 17.80% |
| 2004-03-31 | $0.08B | $0.45B | 17.75% |
| 2003-12-31 | $0.08B | $0.42B | 19.18% |
| 2003-09-30 | $0.08B | $0.40B | 19.73% |
| 2003-06-30 | $0.08B | $0.37B | 20.78% |
| 2003-03-31 | $0.07B | $0.35B | 20.87% |
| 2002-12-31 | $0.05B | $0.32B | 15.84% |
| 2002-09-30 | $0.04B | $0.31B | 13.76% |
| 2002-06-30 | $0.03B | $0.29B | 11.66% |
| 2002-03-31 | $0.03B | $0.27B | 10.15% |
| 2001-12-31 | $0.04B | $0.24B | 14.77% |
| 2001-09-30 | $0.03B | $0.20B | 15.40% |
| 2001-06-30 | $0.00B | $0.16B | -2.56% |
| 2001-03-31 | $-0.01B | $0.08B | -6.47% |
| 2000-12-31 | $-0.01B | $0.02B | -49.44% |
| 2000-09-30 | $-0.02B | $-0.04B | 51.06% |
| 2000-06-30 | $0.01B | $-0.06B | -20.00% |
| 2000-03-31 | $0.01B | $-0.03B | -33.59% |
| 1999-12-31 | $0.02B | $-0.03B | -61.82% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $13.038B | $4.015B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $142.882B | 25.03 |
| CVS Health (CVS) | United States | $122.206B | 12.19 |
| HCA Healthcare (HCA) | United States | $92.119B | 14.32 |
| Elevance Health (ELV) | United States | $92.005B | 14.44 |
| Cencora (COR) | United States | $62.254B | 19.02 |
| Natera (NTRA) | United States | $49.267B | 0.00 |
| Labcorp Holdings (LH) | United States | $25.572B | 18.03 |
| Viatris (VTRS) | United States | $19.136B | 6.61 |
| Medpace Holdings (MEDP) | United States | $16.619B | 34.90 |
| DiDi Global (DIDIY) | China | $16.275B | 178.51 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $16.114B | 0.00 |
| Solventum (SOLV) | United States | $15.290B | 12.65 |
| Revvity (RVTY) | United States | $14.338B | 24.02 |
| ICON (ICLR) | Ireland | $12.935B | 17.58 |
| BrightSpring Health Services (BTSG) | United States | $11.931B | 41.02 |
| Avantor (AVTR) | United States | $10.254B | 18.49 |
| BioMerieux (BMXMF) | France | $10.192B | 0.00 |
| HealthEquity (HQY) | United States | $7.944B | 25.89 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.362B | 72.36 |
| PACS (PACS) | United States | $7.051B | 23.70 |
| Sonic Healthcare (SKHHY) | Australia | $6.687B | 0.00 |
| GETINGE (GNGBY) | Sweden | $6.654B | 18.79 |
| CochLear (CHEOY) | Australia | $6.355B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.282B | 23.76 |
| MiniMed (MMED) | United States | $6.181B | 0.00 |
| Sotera Health (SHC) | United States | $5.285B | 21.79 |
| Concentras Parent (CON) | United States | $4.566B | 22.52 |
| Organon (OGN) | United States | $3.585B | 4.55 |
| CareDx (CDNA) | United States | $2.709B | 308.06 |
| Alignment Healthcare (ALHC) | United States | $2.684B | 68.11 |
| GeneDx Holdings (WGS) | United States | $2.676B | 249.28 |
| Amplifon S.p.A (AMFPF) | Italy | $2.466B | 12.74 |
| Pediatrix Medical (MD) | United States | $2.187B | 12.81 |
| Establishment Labs Holdings (ESTA) | United States | $2.143B | 0.00 |
| Progyny (PGNY) | United States | $2.137B | 30.27 |
| COMPASS Pathways (CMPS) | United Kingdom | $2.013B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $1.914B | 0.00 |
| Surgery Partners (SGRY) | United States | $1.838B | 70.20 |
| Bora Pharmaceuticals, - (BORAY) | Taiwan | $1.695B | 10.18 |
| Freenome (FRNM) | United States | $1.607B | 0.00 |
| Ardent Health (ARDT) | United States | $1.552B | 8.87 |
| Agilon Health (AGL) | United States | $1.551B | 0.00 |
| Nutex Health (NUTX) | United States | $1.486B | 8.52 |
| InnovAge Holding (INNV) | United States | $1.470B | 0.00 |
| Omada Health (OMDA) | United States | $1.255B | 256.25 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.241B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.220B | 23.73 |
| Teladoc Health (TDOC) | United States | $1.181B | 0.00 |
| CryoPort (CYRX) | United States | $0.808B | 0.00 |
| GMR Solutions (GMRS) | United States | $0.716B | 0.00 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| Forward Industries (FWDI) | United States | $0.513B | 0.00 |
| Oncology Institute (TOI) | United States | $0.507B | 0.00 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.504B | 0.00 |
| Strata Critical Medical (SRTA) | United States | $0.474B | 0.00 |
| SBC Medicals (SBC) | United States | $0.467B | 9.66 |
| Shoulder Innovations (SI) | United States | $0.382B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.377B | 5.47 |
| Embecta (EMBC) | United States | $0.297B | 2.57 |
| Biodesix (BDSX) | United States | $0.289B | 0.00 |
| So-Young (SY) | China | $0.266B | 0.00 |
| LifeMD (LFMD) | United States | $0.166B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.109B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.101B | 0.00 |
| SkinHealth Systems (SKIN) | United States | $0.091B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.079B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.065B | 7.65 |
| Tevogen (TVGN) | United States | $0.049B | 0.00 |
| DocGo (DCGO) | United States | $0.037B | 0.00 |
| Lifeward (LFWD) | United States | $0.020B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.014B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.014B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.011B | 0.00 |
| Ainos (AIMD) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| Aclarion (ACON) | United States | $0.007B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.007B | 0.00 |
| 20/20 Biolabs (AIDX) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| Pomdoctor - (POM) | China | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.004B | 0.00 | |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |